Company Overview
Ernexa Therapeutics Inc. operates as a preclinical-stage biotechnology entity dedicated to developing induced mesenchymal stem cells (iMSC) therapies designed to treat cancer and autoimmune diseases. The company's primary focus is on its lead product, ERNA-101, which functions as an allogenic pro-inflammatory cytokine secreting iMSC intended for the secretion of IL-7/IL-15. This enterprise functions within the broader Healthcare sector, specifically navigating the specialized Biotechnology industry where innovation often precedes commercial viability. Currently, the company maintains a market capitalization of $5.89M and employs 5 individuals to drive its research and development initiatives. These financial figures indicate that Ernexa Therapeutics is a micro-cap entity with minimal revenue generation, reflecting the typical early-stage nature of biotechnology firms that prioritize product development over immediate profitability.
Financial Health
The company reported a Net Income of $-14,100,000 over the trailing twelve months, while its Revenue and EBITDA figures are not available in the provided data. The significant negative Net Income relative to the unreported revenue highlights a cost structure dominated by research, development, and operational expenses that far exceed current income streams. Free Cash Flow stands at $-4,576,250, which indicates a substantial cash outflow required to sustain operations and fund the preclinical pipeline without generating positive cash returns. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, signifying that the company has not yet achieved profitable operations or scaled revenue sufficiently to cover costs. On the balance sheet, the company holds $1.88M in cash against $490,000 in debt, resulting in a Debt to Equity ratio of 20.41, which suggests a capital structure heavily reliant on equity financing rather than leverage. The Current Ratio is 1.01, indicating that the company possesses just enough current assets to cover its current liabilities, presenting a tight liquidity position that requires careful cash management. Return on Equity is -686.7% and Return on Assets is -104.9%, metrics that reveal management is currently generating significant losses on every dollar of equity and assets deployed.
Valuation Assessment
The company presents a Trailing P/E Ratio of N/A and a Forward P/E of -0.02, reflecting the absence of positive earnings and the pre-revenue or pre-profit status of the biotechnology firm. The negative Forward P/E implies that analysts or data models are projecting continued losses or that the denominator for the forward calculation is not yet positive, precluding a traditional earnings-based valuation. The Price to Book ratio is 0.66, indicating that the market values the company at 66% of its net book value, which is common for distressed or pre-revenue companies but also suggests a lack of market premium over the theoretical liquidation value. Alternative valuation metrics such as Price to Sales are N/A due to the lack of reported revenue, while the EV/EBITDA stands at -0.49, further confirming that the company is not currently generating operating profits to support a standard enterprise value multiple. The stock has traded between a 52-Week High of $4.05 and a 52-Week Low of $0.20, placing the current price at the lower end of this historical range relative to the recent highs. The Beta value is 6.87, which signifies that the stock price is highly volatile and moves with extreme intensity relative to the broader market, amplifying both potential gains and losses during market fluctuations.
Growth & Income
Revenue Growth and Earnings Growth are both listed as N/A, meaning historical growth rates cannot be calculated from the available trailing twelve months data. Without positive earnings, the concept of earnings growing faster or slower than revenue is not applicable in a traditional sense, as the company is still in the phase of investing capital to build its pipeline rather than scaling profitable operations. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that all available cash is being reinvested into the company's growth initiatives rather than distributed to shareholders. This non-dividend profile is standard for preclinical-stage biotechnology companies that must conserve capital for drug development and regulatory processes. Consequently, the overall growth and income profile is characterized by a total reinvestment strategy with no current income generation, focusing entirely on advancing the ERNA-101 therapy through preclinical stages.